Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cells by Molinaro, Ross J. et al.
Selection and cloning of poly(rC)-binding protein
2 and Raf kinase inhibitor protein RNA activators
of 20,50-oligoadenylate synthetase from prostate
cancer cells
Ross J. Molinaro
1,2, Babal Kant Jha
2, Krishnamurthy Malathi
2,
Sooryanarayana Varambally
3,4, Arul M. Chinnaiyan
3,4 and Robert H. Silverman
2,*
1DepartmentofChemistry,ClevelandStateUniversity,EuclidAvenueatEast24thStreet,Cleveland,OH44115,USA,
2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland,
OH 44195, USA,
3Departmentof Pathology and
4DepartmentofUrology,UniversityofMichiganMedicalSchool,1400
E Medical Center Drive, Ann Arbor, MI 48109, USA
Received August 16, 2006; Revised October 9, 2006; Accepted October 16, 2006
ABSTRACT
The antiviral and antitumor functions of RNase L
are enabled by binding to the allosteric effectors
50-phosphorylated, 20,50-linked oligoadenylates (2-5A).
2-5A is produced by interferon-inducible 20,50-
oligoadenylate synthetases (OAS) upon activation
by viral double-stranded RNA (dsRNA). Because
mutations in RNase L have been implicated as risk
factors for prostate cancer, we sought to determine
if OAS activators are present in prostate cancer
cells. We show that prostate cancer cell lines (PC3,
LNCaP and DU145), but not normal prostate epithe-
lial cells (PrEC), contain RNA fractions capable
of binding to and activating OAS. To identify the
RNA activators, we developed a cDNA cloning
strategy based on stringent affinity of RNAs for
OAS. We thus identified mRNAs for Raf kinase
inhibitor protein (RKIP) and poly(rC)-binding protein
2 (PCBP2) that bind and potently activate OAS. In
addition, human endogenous retrovirus (hERV)
envelope RNAs were present in PC3 cells that bind
and activate OAS. Analysis of several gene expres-
sion profiling studies indicated that PCBP2 RNA
was consistently elevated in metastatic prostate
cancer. Results suggest that OAS activation may
occur in prostate cancer cells in vivo stimulated by
cellular mRNAs for RKIP and PCBP2.
INTRODUCTION
Interferons (IFNs) are a group of cytokines that confer anti-
viral and antiproliferative effects by arming the cell with
numerous defense mechanisms, including the 20,50-oligo-
adenylate synthetase (OAS)/RNase L system (1). Unusual
50-phosphorylated, 20,50-oligoadenylates (2-5A) are produced
from ATP by IFN-inducible OAS proteins in response to
stimulation by dsRNA activators (2,3). To date, all naturally
occurring RNA activators of RNase L that have been identi-
ﬁed are dsRNA structures of various viral origins (4–8). RNA
activation of OAS precedes and is required for the activation
of RNase L. Latent RNase L, present in most mammalian
cells, is a monomer lacking ribonuclease activity (9,10).
However, upon binding 2-5A, RNase L dimerizes into a
potent endoribonuclease that degrades single-stranded
regions in viral and cellular RNAs after UpNp dinucleotide
sequences (primarily UU and UA), and sequences within
the L1 bulge of intact cellular 28S rRNA (10–13). The
OAS/RNase L pathway is required for a complete innate
antiviral response. Accordingly, mice lacking RNase L have
a reduced ability to survive infections by any one of several
different types of viruses, including Coxsackievirus B4,
encephalomyocarditis virus and West Nile virus (14–16).
Although transient activation of RNase L is compatible
with cell survival, sustained activation is not (17–20).
RNase L activity can result in apoptosis, an outcome that
requires the MAP kinase, JNK, and is characterized by
cytochrome c release from mitochondria and caspase activa-
tion (17,19). Prostate cancer cells deﬁcient in RNase L
are highly resistant to apoptosis by the RNase L activator,
2-5A, alone or in combination treatments with a topoiso-
merase I inhibitor and tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) (18). While apoptosis
eliminates virus-infected cells, a result consistent with the
antiviral activity of RNase L, it can also function as a
tumor suppressor mechanism. Interestingly, in several, but
not all studies, mutations and variants of RNASEL were cor-
related with enhanced risk of prostate cancer (21–27). For
instance, the common variant of RNase L, R462Q, was
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(22). Recently, we identiﬁed a novel gammaretrovirus,
XMRV, almost exclusively in prostate tumors homozygous
for a reduced activity variant (R462Q) of RNase L (28).
Those ﬁndings suggested that XMRV is susceptible to the
OAS/RNase L pathway, thus providing evidence for an
antiviral role of RNase L in humans.
IFN treatment of human cells results in transcription of a
cluster of four OAS genes (OAS1, OAS2, OAS3 and OASL)
located on chromosome 12q24.2, which encodes 8–10 latent
isoforms of OAS, as a result of alternative splicing (29).
Once activated, OAS proteins (excluding OASL), catalyze
20-speciﬁc adenosine nucleotidyl transfer reactions with ATP
as a substrate. However, the reason for multiple isoforms of
OAS with essentially similar function remains unknown.
OAS1 and OAS2 encoded proteins produce predominantly
2-5A trimer and longer oligomers, all of which activate
RNase L (30). In contrast, OAS3 encoded proteins produce
mostly 2-5A dimer, ppp50A20p50A, which does not activate
RNase L (31). Although dsRNAs, such as poly(I):poly(C),
are potent activators of OAS, both dsRNA and ssRNA can
bind to, and in some instances activate, OAS (32). Activation
of OAS was proposed as a two-step process based upon the
observation that the binding afﬁnities of different in vitro
selected ssRNA aptamers do not correlate with OAS activation
potential and the elucidation of the crystal structure of porcine
OAS1 (32,33).
Although viral dsRNAs potently activate OAS, IFN treat-
ment by itself inhibits the growth of certain cancer cells,
some of which may not be virus infected or may not be
dependent on viral infections for cell growth (34). Unidenti-
ﬁed nuclear RNA activators of OAS were detected in IFN-
sensitive cancer cells but not normal cells, suggesting that
these RNAs may play a role in cellular growth arrest (35).
The recent identiﬁcation of RNASEL as a prostate cancer sus-
ceptibility gene led us to examine the possible presence of
RNA activators of OAS in prostate cancer cells (21). To
identify such RNAs, we developed a cDNA cloning strategy
based on high afﬁnity of RNA for OAS. These efforts identi-
ﬁed two RNA activators of OAS in prostate cancer cells
encoding Raf kinase inhibitor protein (RKIP) (36) and
poly(rC)-binding protein 2 (PCBP2) (37).
MATERIALS AND METHODS
Cell culture
Cell lines: LNCaP-FGC (ATCC Catalog no. CRL-1740),
DU145 (ATCC Catalog no. HTB-81) and PC3 (ATCC
Catalog no. CRL-1435) were grown in RPMI 1640 medium
with 2 mM L-glutamine, fetal bovine serum 10%; 100 U/ml
penicillin G and 100 mg/ml streptomycin. Normal prostate
epithelial cells (PrEC) were obtained from Clonetics Cor-
poration (San Diego, CA) and were maintained in prostate
epithelial cell medium (PrEGM) supplemented with a mix-
ture of various growth factors (SingleQuots) (Clonetics);
and 10% fetal bovine serum.
Human recombinant OAS1 and RNase L: Escherichia coli
(BL21-DE3 Novagen, EMD Biosciences, Inc., USA) was
transformed with recombinant human His6-tagged OAS1
p42 cDNA in a modiﬁed pET9d plasmid (a gift from Rune
Hartmann, University of Aarhus, Denmark) and grown over-
night in Luria–Burtani (LB) broth containing 30 mg/ml kana-
mycin. An aliquot of 5 ml of the overnight culture was
inoculated in 1 liter LB containing antibiotic and allowed
to grow at 37 C until the OD600 reached 0.6. The culture
was cooled on ice and human OAS was induced with
0.5 mM IPTG at 25 C for 12 h with constant shaking at
220 r.p.m.. The cells were harvested by centrifugation at
10000 g for 10 min and washed with chilled phosphate-
buffered saline (PBS). The cells were re-suspended in buffer
A: [50 mM sodium phosphate buffer (pH 8.0), 300 mM
sodium chloride, 5 mM magnesium chloride, 20 mM imida-
zole, 10% glycerol and 5 mM 2-mercaptoethanol] plus 0.1%
NP-40 and EDTA-free complete protease inhibitor cocktail
(Roche Diagnostics Corporation, Indianapolis, IN, USA)
and lysed using a French press. Cell debris was removed by
centrifugation at 20 000 g for 20 min and the lysate was
loaded on Nickel(II) nitrilotriacetic acid (Ni
2+-NTA) agarose
HiTrap  Chelating HP column (Amersham Biosciences)
washed with buffer A and eluted with the same buffer con-
taining 250 mM imidazole (buffer B). The eluate was dia-
lyzed at least four times against buffer C: [10 mM HEPES
(pH 7.4), 150 mM sodium chloride, 5 mM magnesium chlo-
ride, 5 mM 2-mercaptoethanol and 0.005% surfactant P20]
and further puriﬁed with size exclusion chromatography
with a Superdex HR16/60 column in buffer C. Human recom-
binant RNase L was expressed in Sf9 insect cells (Invitrogen)
from a baculovirus vector and puriﬁed to homogeneity as
described previously (38).
RNA isolation
Total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and DNA was digested with RNase-
free DNase I (Ambion, Austin, TX, USA). Poly(A)
+ RNA
was isolated with the Oligotex mRNA Midi Kit (Qiagen).
RNA concentrations were measured with the RIBOgreen
quantiﬁcation kit (Molecular Probes, Invitrogen).
2-5A synthesis assays
2-5A synthesis reaction mixtures, prepared in DEPC-treated
H2O, contained OAS buffer [20 mM HEPES (pH 7.6),
20 mM magnesium acetate, 20 mM potassium chloride and
1 mM EDTA], 10 mM ATP (Sigma-Aldrich Inc., USA)
(pH 7.4), 2 mg/ml RNA and 20 mg/ml OAS. Samples were pre-
pared on ice, mixed, centrifuged brieﬂy and incubated at 37 C
for the indicated time. Control reactions were prepared exactly
as described above, except either without ATP, or without
both ATP and OAS. 2-5A synthesis reactions were passed
through a Centricon-10 ﬁlter (Millipore Corp.). 2-5A in each
sample was measured with an RNase L-dependent FRET
assay as described previously (38). To generate a standard
curve, authentic trimeric 2-5A, diluted to ﬁnal concentrations
of 0.1, 0.3, 1, 3, 10, 30, 100 and 300 nM in DEPC-treated
water was used. Fluorescence was measured at 5, 30, 60, 90
and 120 min with a Wallac 1420 ﬂuorimeter (Perkin-Elmer
LAS Inc., USA) (absorption 485 nm/emission 535 nm).
In vitro selection of the OAS-binding RNAs
All solutions were made with DEPC-treated H2O. The buffer
in the OAS preparations was exchanged with OAS buffer
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2+-NTA agarose
(Novagen, EMD Bioscience), equilibrated in OAS buffer
without EDTA, was incubated with OAS for 30 min. The
OAS–resin complex was washed with 500 ml of OAS buffer
minus EDTA. OAS was repeatedly (5–7 times) added to the
complex until the Ni
2+-NTA agarose was saturated with
OAS. PC3 Poly(A)
+ RNA, at a molar ratio of 25:1 to
bound OAS, was used in the in vitro selection assays. RNA
was added to the OAS–resin complex and incubated for
15 min and mixed manually every 2 min. The sample was
washed twice with 500 ml of OAS buffer minus EDTA.
The RNA–OAS–resin complex was washed with 100 mlo f
the same buffer supplemented with 250 mM potassium chlo-
ride followed by two washes with 500 ml of OAS buffer
minus EDTA. The RNA–OAS complex was removed from
the resin by adding 250 ml strip buffer [20 mM Tris–HCl
(pH 8.0), 100 mM sodium chloride and 100 mM EDTA] in
DEPC-treated H2O. Imidazole was not used due to possible
site-speciﬁc cleavage of RNAs (39). The supernatant was
added to 250 ml of protein digestion buffer [50 mM Tris–
HCl (pH 7.5), 5 mM calcium chloride and 0.5% SDS] and
treated with 100 mg/ml Proteinase K (Promega Corp.,
Madison, WI, USA) at 37 C for 90 min. The samples were
extracted with an equal volume of phenol/chloroform/
isoamyl alcohol (25:24:1), pH 6.6 (Ambion) and the selected
RNAs were precipitated with 300 mM sodium acetate, pH
5.2, and 2.5 volumes of 100% ethanol with 10 mg glycogen
as a carrier. The RNA was washed with 75% ethanol and
air-dried. The pellet was dissolved in DEPC-treated H2O,
puriﬁed and concentrated with the RNeasy  MinElute
Cleanup Kit (Qiagen). OAS was monitored by loading
aliquots of washes, beads or supernatant onto a 10% SDS–
PAGE, and subsequent silver-staining (Bio-Rad Inc., Hercules,
CA, USA). Control mock binding experiments were run in
parallel without the addition of OAS to determine if RNA
species capable of activating OAS were non-speciﬁcally
binding to the Ni
2+-NTA agarose. RNA isolated from the
in vitro selection experiments with and without OAS were
quantitated with the RIBOgreen quantiﬁcation kit and analyzed
for their ability to activate OAS with the 2-5A synthesis reac-
tions. 2-5A levels in samples were quantiﬁed in FRET assays.
cDNAs preparation and cloning
Selected RNAs were annealed with either random hexamer or
oligo(dT) primers, and cDNAs were obtained by reverse tran-
scription. First-strand synthesis was performed for 1 h at
55 C with Superscript  Choice System for cDNA Synthesis
(Invitrogen). Second-strand synthesis was performed accord-
ing to the manufacturer’s instructions except without the
addition of linkers. Three control reactions were carried out
in parallel with each RT–PCR. The ﬁrst control was without
the addition of selected RNA; the second control was without
reverse transcriptase; and the third control was without the
addition of primers. The PCR products were cloned into
pBluescript KS
+. The recombinant clones were sequenced
and identiﬁed using the BLAST site at www.ncbi.nih.gov.
Primers speciﬁc for hERV env RNAs, as described previ-
ously (40), were used in PCR (Promega PCR Master Mix)
with 2 ml of the cDNA produced from PC3 total or selected
RNA (described above). Control reactions included PCR with
cDNAs generated without RNA, PCR on cDNA with RNA
recovered from mock in vitro selection assay, and PCR
for GAPDH. Primers for PCR were as follows. GAPDH
exon 8; forward d(CCAAGGCTGTGGGCAAGG), reverse
d(TCCGACGCCTGCTTCACC), b-actin; forward d(GCCA-
GCTCACCATGGATGAT), reverse d(TTTAAGGTGTGCA-
CTTTTATTC), PCBP2; forward d(CACCGGTGTGATTG-
AAGG forward d(CACAATGTGATTTTATGGT), reverse
d(TCTTCATTCAGGTTTCTAT). PCRs were as follows:
95 C, 4 min, [95 C, 30 s (annealing temperature 45 s),
72 C, 1 min] for 30 cycles, 72 C, 10 min. Annealing tem-
perature for GAPDH was at 53 C; ERV3 env was 63 C;
hERV 4-1 SU env was 55 C; hERV 4-1 TM env was
58 C; b-actin was 50 C; PCBP2 was 52 C and RKIP was
46 C. The selected cDNAs were cloned into pGEM -T
Easy (Promega Corp.).
Northern blots
Twenty micrograms of PC3, LNCaP, DU145 and PrEC RNA
were separated on 1.2% agarose formaldehyde gels and
transferred to Hybond-N
+ (Amersham Pharmacia Biotech)
membranes. The transferred membranes were hybridized
with [a-
32P]dCTP-labeled probes. cDNA probes speciﬁc for
PCBP2, RKIP and GAPDH were generated using Prime-It 
RmT Random Primer Labeling Kit (Stratagene). Hybridized
membranes were exposed to ﬁlm (Kodak BioMax XAR
Film) for 12–48 h at  80 C. Blots were stripped in four
washes of boiling 0.1· SSC [0.3 M sodium chloride and
0.03 M sodium citrate (pH 7.0)], 0.1% SDS for 5 min.
Preparation of RNAs
RNA was prepared from linearized plasmids by runoff T7
RNA polymerase transcription reactions as described previ-
ously (41) then resolved on a formaldehyde–agarose gel
and eluted using a crush-and-soak method at 4 C. The
RNA was extracted with an equal volume of phenol/
chloroform/isoamyl alcohol (25:24:1), pH 6.6 (Ambion), pre-
cipitated with 300 mM sodium acetate (pH 5.2) and 2.5 vol-
ume of 100% ethanol and dissolved in DEPC-treated H2O.
Aliquots of the puriﬁed RNAs were run on formaldehyde
gels to conﬁrm RNA integrity. The RNAs used in subsequent
assays were ﬁrst denatured at 70 C and cooled at room tem-
perature for 15 min to allow renaturation. The puriﬁed
selected RNAs were used in 2-5A synthesis assays and sur-
face plasmon resonance (SPR) assays. Poly(I):poly(C) was
obtained from Amersham Bioscience.
Surface plasmon resonance
Kinetic characterization of OAS:RNA binding was performed
with SPR on a Biocore 3000 (Biacore Inc., USA). The
response units, RU, indicating the extent of binding, were
monitored with time. For this purpose, NTA chips (Biacore
Inc.) were saturated with Ni
2+ solution to achieve a baseline
shift of >40 response units (RU). The puriﬁed His6-tagged
OAS1 p42 (200 ng/ml) in 10 mM HEPES (pH 7.4) containing
5 mM magnesium chloride, 150 mM sodium chloride, 10 mM
EDTA and 0.005% surfactant P20 (SPR buffer; Biacore Inc.)
was immobilized on Ni
2+-NTA Biacore sensorchip at a ﬂow
rate of 10 ml/min for 1 min at 25 C to achieve a resonance
response of 250–300 RU. An additional wash for 5 min at
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in vitro transcribed, gel-puriﬁed RNAs were dissolved in
DEPC-treated water and freeze-dried. The freeze-dried
RNAs were dissolved in SPR buffer to make a stock of
10 mM RNA. Different concentrations of RNAs (0.1, 0.5, 1,
5, 10, 25, 50 and 100 nM) were prepared and passed over the
OAS immobilized sensorchip at a ﬂow rate of 10 ml/min for
1 min while association was monitored. The dissociation was
monitored with buffer alone for additional 5 min. Data nor-
malization against buffer alone, analysis and ﬁtting was per-
formed with BIAevaluation  software, version 3.2 (Biacore
Inc.) with the option for simultaneous ka/kd calculation.
Fitting of sensorgram data was carried out according to global
ﬁtting, and the ka and kd values were calculated with a 1:1
Langmuir model. In addition, these data were also used for
independent KD calculations by Scatchard plot analysis.
High-performance liquid chromatography (HPLC)
2-5A synthesis reaction mixtures were passed through a
Centricon-10 ﬁlter (Millipore Corp.) to remove the protein
and RNA before HPLC. Fifty microliter of a 1:10 dilution
of clariﬁed 2-5A synthesis reaction mixtures in 20 mM
Tris–HCl (pH 7.5) were loaded onto a Dionex P100 analytical
HPLC column, interfaced with Beckman System Gold HPLC
system connected to a 32 Karat workstation, at a ﬂow rate of
1 ml/min and eluted with a linear gradient of 0–750 mM
NaCl over a period of 1 h. The chromatograms were analyzed
with 32 Karat software (Beckman-Coulter).
In silico validation of RKIP and PCBP2 expression
We interrogated RKIP and PCBP2 expression in the
ONCOMINE public microarray database (42), which con-
tains transcription proﬁling of 35 different tumors and
14177 microarrays proﬁling for these different tumors. We
selected prostate cancer proﬁling studies from this database
for expression analysis of RKIP and PCBP2.
RESULTS
RNA activators of OAS in prostate cancer cells
To monitor and compare RNA activators of OAS in prostate
cancer and normal cells, we isolated RNA from three estab-
lished human prostate cancer cell lines (PC3, LNCaP and
DU145) and normal prostatic epithelial cells (PrEC). RNA
was incubated with puriﬁed histidine-tagged human OAS1
(subsequently ‘OAS’) while conversion of ATP to 2-5A
was determined by measuring activation of RNase L in
FRET assays (Materials and Methods). 2-5A levels were
calculated from relative ﬂuorescence units, corresponding to
RNA cleavage, when compared to a standard curve generated
with known amounts of authentic 2-5A trimer. RNA quality
and integrity was established by separation on RNA chips
with an Agilent bioanalyzer (data not shown). Remarkably,
amounts of 2-5A were 9- to 12-fold higher in OAS reactions
containing RNA isolated from the three prostate cancer cell
lines (PC3, LNCaP, DU145) in comparison to reactions
with RNA isolated from normal prostate epithelial RNA
(PrEC) (Figure 1). 2-5A synthesis was dependent on the pres-
ence of OAS, RNA and ATP. The highest level of OAS
activation (2 h incubation at 37 C) was obtained with PC3
RNA (5.8 nmol 2-5A/mg total RNA), whereas the RNA
isolated from LNCaP and DU145 cells produced 4.4
and 4.7 nmol 2-5A/mg total RNA, respectively. In contrast,
RNA from the PrEC cells produced only  0.5 nmol
2-5A/mg RNA. Because PC3 RNA reproducibly showed the
highest OAS activating potential, we used RNA from these
cells to clone RNA activators of OAS.
RNA activators of OAS are present in the
poly(A)
+ fraction of PC3 cell RNA
To determine whether the PC3 RNA responsible for OAS
activation was mRNA, poly(A)
+ and poly(A)
  RNA fractions
were compared (Figure 2). The poly(A)
+ RNA fraction clearly
contained the OAS activator(s) since it had a 15-fold higher
speciﬁc activity in the OAS assay than the poly(A)
  RNA
(Figure 2A). Curiously, however, the speciﬁc activity of the
poly(A)
+ RNA was slightly lower than that of the total
RNA, despite being enriched for the OAS-activating species.
These results suggest that there may be RNA species
inhibitory to OAS in the poly(A)
+ RNA fraction.
To isolate RNA species in the PC3 poly(A)
+ RNA fraction
that have high afﬁnity for OAS, we developed an in vitro
selection method (Materials and Methods). Binding and elu-
tion of OAS to and from the Ni
2+-NTA beads during the
RNA binding and washing procedures was monitored by gel
electrophoresis and silver staining of the OAS (Figure 2B).
These methods included a KCl wash to remove any RNA spe-
cies that bind OAS with low afﬁnities. The bound RNA,
recovered after proteinase K digestion of the OAS, produced
4.8 nmol 2-5A/mg RNA when incubated with freshly added
OAS, while <50 pmol 2-5A/mg RNA was produced by OAS
from RNA recoveredwith Ni
2+-NTA agarose alone (Figure 3).
Cloning and identification of PC3 mRNAs
that activate OAS
To clone and identify the RNA species that bind OAS, we
performed reverse transcription using the PC3 poly(A)
+
Figure 1. Activation of OAS by total RNA isolated from prostate cancer cell
lines. Total RNA preparations from prostate cancer cell lines (A, B and C:
PC3, LNCaP, DU145, respectively) or normal prostate epithelial cells (D,
PrEC) were incubated with OAS and ATP at 37 C for 2 h and 2-5A was
measured by FRET assay as described (Materials and Methods). Control
reactions were without ATP and/or OAS. Linear regression analysis was used
to fit the standard curve data points within 95% confidence limits.
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RNA(s) that bind to and activate OAS are double-stranded
or have a deﬁned secondary structure. Therefore, reverse
transcription at lower temperatures may not allow efﬁci-
ent cDNA synthesis. Accordingly, the temperature of the
ﬁrst-strand synthesis reaction was performed at 55 C. To
maximize the amount of clones produced, separate reverse
transcription reactions were performed with either random
hexamer or oligo(dT) primers. Using this strategy, only
two clones were obtained from  16 rounds of selection
and cloning. The two clones were sequenced and identiﬁed
as partial cDNAs for RKIP and PCBP2. The RKIP cDNA,
368 nt in length, was from the 30-UTR [nt 1138–1506;
GenBank accession no. NM_002567] whereas the PCBP2
cDNA, 72 nt in length, was from the 50 region of the
ORF (356–428 nt, translation start site at 351 nt; GenBank
accession no. AB188306). The RKIP clone was produced
using oligo(dT) primed reverse transcription, while the
PCBP2 encoding clone was produced using random hexamer
primers.
The level of expression of the selected RNAs in the pros-
tate cancer cell lines and PrEC was determined in northern
blots. Levels of PCBP2 mRNA were highly elevated (>10-
fold) in the prostate cancer cells (PC3, LNCaP and DU145)
compared with the normal (PrEC) cells after normalizing
for levels of GAPDH mRNA (Figure 4). The PCBP2 cDNA
probe identiﬁed a doublet produced from alternative splicing.
However, while normalized levels of RKIP mRNA were ele-
vated in the PC3 cells (6-fold), they were not elevated in the
LNCaP and DU145 cells.
hERV env RNAs bind OAS
A report of the presence of hERV RNAs in prostate cancer
cells, and the recognition that viral RNAs often activate
OAS, led us to examine if such RNAs were capable of bind-
ing and activating OAS (40). Therefore, RT–PCR was per-
formed for hERV env RNAs with PC3 poly(A)
+ RNA
fractions isolated by OAS-selection. PCR primers were spe-
ciﬁc for the env regions of hERV 4-1 transmembrane  
(599 bp) (nt 7501–8099; GenBank accession no. M10976),
hERV 4-1 surface subunit (SU) (1349 bp) (nt 6211–7559;
GenBank accession no. M10976) and ERV3 (1745 bp)
(nt 786–2530; GenBank accession no. M12140), previously
identiﬁed in prostate cancer (40). RNA initiated PCR per-
formed with both total RNA and OAS-selected RNA from
PC3 cells showed the presence of hERV 4-1 TM and SU
Figure 2. In vitro selection of poly(A)
+ RNA species that bind OAS. (A)
Activation of OAS with poly(A)
+ and poly(A)
  fractions of PC3 RNA. OAS
reactions were at 37 C for 2 h. 2-5A levels were determined by FRET assay.
(B) Binding and elution of OAS from Ni
2+-NTA agarose as determined by
SDS–PAGE and silver-staining of gel. Lane 1, purified OAS; lane 2, input
OAS; lane 3, wash of OAS:Ni
2+-NTA beads; lane 4, aliquot of the OAS:Ni
2+-
NTA beads; lane 5, effluent after loading PC3 poly(A)
+ RNA; lanes 6 and 7,
consecutive washes of RNA:OAS:Ni
2+-NTA beads with buffer; lane 8, KCl
wash of RNA:OAS:Ni
2+-NTA beads; lanes 9 and 10, additional washes of
RNA:OAS:Ni
2+-NTA beads; lane 11, elution of RNA:OAS with EDTA; lane
12, post-elution wash of beads; and lane 13, proteinase digestion of eluted
OAS to prepare bound RNA.
Figure 3. OAS activation by poly(A)
+ RNA fraction of PC3 cells. (A)
Activation of OAS with the OAS-selected PC3 poly(A)
+ RNA. (B) Lack of
OAS activation with non-specifically selected RNA isolated from PC3 cells
on Ni
2+-NTA beads without the addition of His6-tagged OAS. 2-5A levels
were determined by FRET assays. The same concentration of RNA (2 mg/ml)
was used in (A) and (B). OAS reactions were at 37 C for 2 h.
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were obtained when GAPDH primers were used on cDNA
prepared from the OAS-selected RNA indicating that
GAPDH mRNA is a suitable non-speciﬁc RNA control
(Figure 5B, lower panel). In a mock selection, performed in
the absence of OAS, these hERV cDNAs were not ampliﬁed
(Figure 5C). Primers speciﬁc for GAPDH mRNA was per-
formed on PC3 cDNA as a positive control (Figure 5C,
lane 1). These ﬁndings show that the different hERV env
RNAs are present in PC3 cells and that these RNA bind OAS.
OAS-binding affinities of the selected RNAs
To determine afﬁnities of the selected RNAs for OAS, SPR
was performed on a Biacore 3000 instrument (Materials
and Methods). Representative sensograms for RKIP, PCBP2
and hERV 4-1 SU env RNAs show concentration-dependent
steady-state binding to OAS with rapid association/disso-
ciation rates (Figure 6A–C). Global data analyses with
BIAevaluation  software (version 3.2; Biacore Inc.) were
used to determine the dissociation constants (KD) and the
association and dissociation rates (ka and kd, respectively)
(Table 1). Scatchard analyses with SigmaPlot  (version
2000) produced similar KD values (Figure 6D and data not
shown). The quality of the ﬁt was determined by c
2-values,
as well as from the magnitude and distribution of the residu-
als (Table 1) (43). The KD values are in the subnanomolar to
nanomolar range. The highest and lowest afﬁnities (0.9 and
18 nM) were obtained for PCBP2 and hERV 4-1 SU
RNAs, respectively (Table 1). Although there are consider-
able differences in the ka and KD for different RNAs, the
off rates, kd, are very similar. There was no signiﬁcant bind-
ing of the RNAs to the Ni
2+-NTA chip alone (data not
shown).
OAS-selected RNAs potently activate
the catalytic function of OAS
To measure the abilities of the RNAs to activate OAS, they
were produced by in vitro transcription and gel-puriﬁed to
remove contaminants (Materials and Methods). To conﬁrm
RNA size and integrity, RNA species were analyzed by
Figure 5. HERV env RNAs bind to OAS. (A) hERV 4-1 TM, hERV 4-1 env
SU and ERV3 env RNAs in total RNA from PC3 cells as determined by
RT–PCR. Reverse transcription was with random hexamer primer (lanes
labeled ‘R’) or oligo(dT) primer (lanes labeled ‘O’) and PCR was with
primers specific for hERV 4-1 env TM (lanes 2–4), hERV 4-1 env SU (lanes
5–7) or ERV3 env (lanes 8–10). Lanes 2, 5 and 8 were negative controls
without RNA; lower gel, RT–PCR with GAPDH-specific primers as a loading
control. (B) RT–PCR was performed as described for (A) except with OAS-
selected RNA from PC3 cells. Bottom gel, lane 1, PCR with GAPDH-specific
primers on cDNA prepared from PC3 cells as a control; lanes 2–10, PCR with
GAPDH-specific primers did not amplify cDNA prepared from the OAS-
selected RNA. (C) Lack of hERV 4-1 env TM (lanes 3 and 4), hERV 4-1 env
SU (lanes 6 and 7) and ERV3 env (lanes 9 and 10) in cDNA prepared from
the mock selected PC3 poly(A)
+ RNA with Ni
2+-NTA beads lacking OAS.
The amount of RNA for (A), 1 mg; for (B),  350 ng; and for (C),  100 ng as
determined by the ribogreen RNA quantification kit. Equal amounts (2 ml) of
cDNA was used in each RT reaction. Lane 1, PCR with GAPDH-specific
primers on cDNA prepared from PC3 cells as a control. Ld, DNA ladder (1 kb
Plus DNA Ladder; Invitrogen).
Figure 4. Levels of RKIP and PCBP2 mRNAs in prostate cancer cell lines and normal prostate epithelial cells. (A), (B) and (C): Northern blot of PCBP2, RKIP
and GAPDH mRNAs, respectively. (D) Relative levels of PCBP2 and RKIP mRNAs (each normalized to GAPDH mRNA levels) in PC3, LNCaP and DU145
cells expressed as a ratio of the same RNAs in PrEC cells (also normalized for GAPDH mRNA). Relative amounts of RNA were estimated using NIH image
software (version 1.61).
Nucleic Acids Research, 2006, Vol. 34, No. 22 6689formaldehyde gel electrophoresis (Figure 7A). 2-5A produced
in OAS reactions was measured by the ability to activate
RNase L using FRET. The OAS-selected RNA species with
the highest activating abilities were ERV3 env and PCBP2
RNAs, producing 22.5 and 21 nmol 2-5A/mg RNA, respec-
tively. HERV 4-1 SU env, RKIP RNA and hERV 4-1 TM
env produced  16, 15.5 and 6 nmol 2-5A/mg RNA, respec-
tively. In comparison, poly(I):poly(C) and b-actin RNA pro-
duced 37.5 and 3 nmol 2-5A/mg RNA, respectively
(Figure 7B and Table 1). As expected, no 2-5A was produced
in control mixtures lacking OAS and/or ATP. Therefore, all
of the OAS-selected RNAs, with the exception of the
Figure 6. Sensograms for kinetic analysis of OAS binding with RNAs. Net SPR signals as a function of time with different levels (A) RKIP, (B) PCBP2 and
(C) hERV 4-1 SU env RNAs injected to Ni
2+-NTA sensor chips (Biacore Inc.) containing immobilized His6-tagged OAS. Arrows indicate time of injection of
RNA and subsequent wash with buffer alone to monitor dissociation of the RNA. (D) Scatchard plot for binding of RKIP, PCBP2 and hERV 4-1 SU env RNAs
with OAS using SPR data. RU, response units; Req, response unit at equilibrium.
Figure 7. Activation of OAS by selected RNA species. (A) In vitro
transcribed and gel- purified RNAs (as indicated) analyzed by formaldehyde
gel electrophoresis. (B) Activation of OAS was determined with the purified
in vitro transcribed RNAs (as indicated). 2-5A levels were measured by
FRET. Assays were in the presence or absence of OAS and ATP (as
indicated). Reactions were at 37 C for 2 h.
Table 1. Kinetic parameters of RNA interactions with OAS determined by
BIAcore analysis in comparison to OAS activation determined by FRET
assays
RNA KD (M) ka
(M
 1 s
 1)
kd (s
 1) c
2 OAS activation
(nmol 2-5A/mg
RNA)
PCBP2 8.58E 10 1.23E+4 1.06E 5 0.064 20.6 ± 4.2
hERV 4-1
TM env
8.55E 10 1.83E+4 1.56E 5 4.89 6.2 ± 0.6
ERV3 env 8.03E 9 3.63E+3 2.92E 5 2.77 22.5 ± 3.1
Poly(I):poly(C) 7.76E 9 1.25E+3 9.68E 6 0.252 37.4 ± 5.3
RKIP 2.29E 9 4.94E+3 1.13E 5 0.67 15.4 ± 2.8
b-Actin 1.23E 9 9.09E+3 1.12E 5 0.519 3.3 ± 1.3
hERV 4-1
SU env
1.81E 8 5.52E+21 E  5 3.7 16.6 ± 2.5
Sensogram data were analyzed by simultaneous ka/kd calculations with a 1:1
Langmuir model.
6690 Nucleic Acids Research, 2006, Vol. 34, No. 22hERV 4-1 TM RNA, approached or exceeded half the activ-
ity of poly(I):poly(C) and were several-fold more potent than
b-actin RNA.
2-5A oligomer size distribution
To determine amounts of different 2-5A oligomers generated
in the OAS reactions, HPLC was performed (Figure 8 and
Table 2). Representative HPLC proﬁles of 2-5A produced
with RKIP, PCBP2 and hERV 4-1 SU env RNAs as OAS
activators are shown (Figure 8). Poly(I):poly(C) and b-actin
RNA produced the largest and least amounts of functional
2-5A (trimer and longer species) (ppp(A20p)nA, n ¼ 2t o
> 4) (Table 2). The relative abilities of the different RNAs
to cause trimeric or longer oligomers of 2-5A to be synthe-
sized were in agreement with RNase L activation data
(Figure 7 and Table 2).
Levels of RKIP and PCBP2 RNAs in human
prostate and prostate tumors
To compare levels of RKIP and PCBP2 RNA in normal pros-
tate and prostate cancer, we interrogated the expression of
these genes in prostate tumor expression proﬁling studies
from several different research groups using the ONCOMINE
expression proﬁling database (42). ONCOMINE is an oncoge-
nomic database of 14 177 microarrays that proﬁled 35
different types of tumors from which gene expression results
can be mined by a web-based platform. RKIP showed variable
patterns of RNA expression in two independent studies.
Although Dhanasekaran et al. (44) showed downregulation
RKIP in localized and metastatic prostate cancer, Lapointe
et al. (45) showed upregulation of RKIP RNA in lymph
node metastasis, but not in primary tumors (Figure 9A). In
contrast, data from four independent prostate cancer proﬁling
studies indicated upregulation of PCBP2 expression in pros-
tate cancer, particularly in metastatic tumors (Figure 9B).
These data show overexpression of PCBP2 in aggressive pros-
tate tumors in agreement with our ﬁndings from the prostate
cancer cell lines (Figure 4).
DISCUSSION
RNA activators of OAS in prostate cancer cells
Here we provide the ﬁrst identiﬁcation of cellular RNA spe-
cies that activate OAS. Prostate cancer cells, especially from
prostate cancer metastasis, are enriched in RNAs capable of
activating OAS compared with normal prostate epithelial
cells. OAS activation usually leads to stimulation of RNase
L. Because sustained RNase L activity causes apoptosis,
these ﬁndings are consistent with reports of mutations in
RNase L in prostate cancer (21,22,25,26). Alternatively,
defects in apoptosis pathways could render prostate cancer
cells resistant to RNase L activity. Most of the RNAs studied
here (except for hERV4-1 TM) potently activated OAS, with
40–60% of the activity obtained with poly(I):poly(C)
(Figure 7). Our data show there is no clear correlation
between RNA size, binding afﬁnity and OAS activation
(Table 1 and Figure 7). For instance, ERV3 RNA has a
10-fold lower KD than PCBP2 RNA, yet both activate OAS
to the same extent. RKIP and b-actin RNAs have similar
KD’s, yet RKIP RNA is 5-fold more active. These ﬁndings
support a prior report that suggested RNA binding per se is
insufﬁcient for OAS activation (32). Analysis of the crystal
structure of porcine OAS1 led to a model suggesting that
activation of OAS is a two-step process in which RNA
binding induces conformation changes in the catalytic
domain (33).
RKIP and PCBP2 mRNAs potently activate OAS
The two cellular mRNAs capable of binding and activating
OAS encode RKIP and PCBP2. There were no obvious sec-
ondary structure or sequence motif similarities between these
two RNAs (data not shown). RKIP, a member of the phos-
phatidylethanolamine binding protein family (PEBP-2), is an
inhibitor of Raf kinase (46) [reviewed in (36)]. In addition to
inhibiting the Raf-MEK-ERK cascade, RKIP also modulates
G-protein and NF-kB signaling (47,48). RKIP suppresses
prostate cancer metastasis by inhibiting angiogenesis and
cell invasion and by promoting apoptosis (49,50). Enhancing
RKIP levels in metastatic prostate cancer cells decreased inva-
sion, whereas decreasing RKIP expression in non-metastatic
prostate cancer cells increased their ability to invade (49). In
contrast, RKIP does not affect growth of prostate cancer cells
in vitro or the ability to form colonies in soft agar. RKIP
expression is rapidly induced upon chemotherapeutic drug
Figure 8. 2-5A oligomer distribution as determined by HPLC of OAS
reaction products using as activator, RKIP, PCBP2 and hERV 4-1 SU env
RNAs as indicated. Reactions were at 37 C for 2 h. The y-axis, optical
density at 254 nm, is translated upward for the clarity of data. Positions of 2-
5A dimer p3A20p50A, trimer p3(A20p)2A and tetramer p3(A20p)3A are
indicated.
Table 2. Percentage of 2-5A oligomers produced with different RNAs
RNA ATP
(%)
p3(A20p)A
(% dimer)
p3(A20p)A2
(% trimer)
p3(A20p)A >3
(% tetramer
and longer)
Poly(I):poly(C) 13.5 30.5 36.3 19.6
PCBP2 36.6 28.2 27.2 7.7
RKIP 44.5 26.5 25.5 3.5
hERV 4-1 SU env 38.1 30.6 30.2 1
hERV 4-1 TM env 44.8 31.4 22.6 1.2
ERV3 env 30 34 35 6
b-Actin 64.8 32.7 2.4 0
Nucleic Acids Research, 2006, Vol. 34, No. 22 6691treatment in human prostate and breast cancer cells, sensitiz-
ing the cells to apoptosis while decreased the expression of
RKIP confers resistance to chemotherapeutic agents (50). A
recent study showed that RKIP expression was a prognostic
marker for prostate cancer, with low expression of RKIP cor-
relating with a high rate of recurrence based on prostate-
speciﬁc antigen levels (51). These studies suggest that RKIP
may sensitize prostate cancer cells to apoptosis by inhibiting
the Raf/MEK/ERK and NF-kB survival signaling pathways.
It is tempting to speculate an apoptotic function for RKIP
mRNA, by way activating the OAS/RNase L pathway, that
is completely independent of the encoded protein. However,
there was no consistent difference in levels of RKIP mRNA
in the three prostate cancer cell lines and normal prostate epi-
thelial cells (Figure 4). In addition, there were variable levels
of RKIP mRNA in prostate cancer in two microarray studies
(44,45). Therefore, RKIP mRNA does not appear to be
responsible for the higher OAS activation obtained with
total RNA from prostate cancer cell lines compared to normal
prostate epithelial cells (Figure 1).
PCBP2 (also known as hnRNP E2 and aCP-2) is a member
of a family of host proteins with triplicate KH RNA-binding
domains and poly(C)-binding activity. PCBP2 has a range of
cellular functions including mRNA stabilization and control
of both translational initiation and transcription (37). Interest-
ingly, PCBP2 binds to a conserved UC-rich region containing
a CCCUCCC motif in the 30-UTR of the androgen receptor
mRNA, suggesting a role for PCBP2 in modulating AR
mRNA stability and/or translation (52,53). In addition,
PCPB2 is an essential host factor in poliovirus replication
playing roles in both translation initiation and viral RNA syn-
thesis (54). Perhaps OAS and RNase L affect translation or
stability of PCBP2 mRNA and thus indirectly regulate both
virus replication and androgen receptor synthesis. The former
activity is consistent with the antiviral activity of the
OAS/RNase L pathway, while the latter is consistent with
the proposed role of RNase L in prostate cancer pathogenesis.
In this regard, PCBP2 expression was higher in all of the
prostate cancer cell lines that we examined compared with
normal prostate epithelial cells. Furthermore, PCBP2 RNA
levels were elevated in localized and/or metastatic prostate
cancer from four independent microarray studies (45,55–57)
(Figure 9A). These investigations suggest that PCBP2 is a
potential marker for aggressive forms of prostate cancer
and that it could regulate androgen receptor synthesis.
hERV RNAs bind and activate OAS
We identiﬁed three hERV env RNAs that bind with high
afﬁnity and activate OAS. hERVs are descendants of exoge-
nous retroviruses that integrated into genomic DNA of host
germ line cells and account for  8–9% of the total human
genome (58–60). Many functions for hERVs have been pro-
posed, including roles in tumorigenesis, autoimmune diseases
and neurological disorders (61–65). In addition, the fusogenic
properties of a hERV-W envelope protein is utilized for the
formation of the placental syncytiotrophoblast layer (66,67).
hERV transcripts are found in various human tissues (68),
including prostate cancer cells speciﬁcally, but lacking in
normal prostatic tissues (40). However, the pathobiology of
hERV RNAs is poorly understood.
It is likely that the OAS/RNase L pathway suppresses retro-
viral infections. For instance, overexpression of OAS (69) or
RNase L (70) in cultured cells impairs HIV replication, and
suppression of RNase L activity by expression of an RNase
L inhibitor (RLI, ABCE1, HP68) enhances HIV growth in
Figure 9. (A) RKIP and (B) PCBP2 expression in prostate tumors from publicly available cancer microarray studies. Box plots of expression of these genes in
published prostate cancer profiling studies from independent groups (44,45,55–57). Expression array analyses of multiple cancer microarray datasets were
collected and analyzed, and statistical significance was calculated. The data were collected from gene expression array database ONCOMINE (www.oncomine.
org) (42). Dots represent the minimum and maximum values. Class represents the type of tissue in which the expression was measured. Numbers in the study of
Vanaja et al. are the Gleason scores (57).
6692 Nucleic Acids Research, 2006, Vol. 34, No. 22culture (71). OAS is activated by HIV-1 TAR RNA (8). In
addition, we identiﬁed a novel gammaretrovirus, XMRV,
almost exclusively in prostate cancer patients homozygous
for a reduced activity variant of RNase L (28). The fact that
some hERV RNAs are capable of activating OAS suggests
that their role in prostate cancer may be more protective
than destructive by initiating an antiproliferative mechanism
in cancer cells. Nevertheless, further studies are clearly
required to establish the roles of these RNA activators of
OAS in the RNA biology of prostate cancer. Our ﬁndings
show that OAS activators are enriched in prostate cancer. Fur-
thermore, these results demonstrate that both viral and cellular
RNA can possess the ability to bind and activate OAS.
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